Gobind Singh
Stock Analyst at HC Wainwright & Co.
(0.07)
# 3,313
Out of 4,425 analysts
14
Total ratings
11.11%
Success rate
-51.86%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPHM Reneo Pharmaceuticals | Reiterates: Buy | $30 | $1.81 | +1,557.46% | 3 | Sep 8, 2023 | |
| ANAB AnaptysBio | Assumes: Buy | $35 | $23.41 | +49.51% | 1 | Sep 19, 2022 | |
| ELEV Elevation Oncology | Assumes: Buy | $7.5 | $3.28 | +128.66% | 1 | Sep 19, 2022 | |
| IMUX Immunic | Assumes: Buy | $26 | $1.27 | +1,947.24% | 2 | Sep 19, 2022 | |
| PRTA Prothena Corporation | Initiates: Market Outperform | n/a | $21.34 | - | 1 | Nov 19, 2021 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | n/a | $28.23 | - | 4 | Nov 15, 2021 | |
| EVLO Evelo Biosciences | Maintains: Market Outperform | n/a | $0.05 | - | 2 | Nov 2, 2021 |
Reneo Pharmaceuticals
Sep 8, 2023
Reiterates: Buy
Price Target: $30
Current: $1.81
Upside: +1,557.46%
AnaptysBio
Sep 19, 2022
Assumes: Buy
Price Target: $35
Current: $23.41
Upside: +49.51%
Elevation Oncology
Sep 19, 2022
Assumes: Buy
Price Target: $7.5
Current: $3.28
Upside: +128.66%
Immunic
Sep 19, 2022
Assumes: Buy
Price Target: $26
Current: $1.27
Upside: +1,947.24%
Prothena Corporation
Nov 19, 2021
Initiates: Market Outperform
Price Target: n/a
Current: $21.34
Upside: -
Protagonist Therapeutics
Nov 15, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $28.23
Upside: -
Evelo Biosciences
Nov 2, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $0.05
Upside: -